Tag: Curetis AG

Company News: Curetis AG Attracts Forbion and Roche As New Investors

– Series A financing round expanded to €34.1 million –

Curetis AG, an innovative molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic products for infectious diseases, today announced the expansion of its Series A financing round by € 9.6 million. The additional funds increase the round to a total of € 34.1 million and the total capital raised to date to € 36.6 million. The financing was led by Forbion Capital Partners together with Roche Venture Fund. CD-Venture and Curetis ́ management also participated in the round. Holger Reithinger, Partner at Forbion Capital Partners, has joined Curetis’ Board of Directors. Roche will get an observer seat on the Board of Directors.

Since its inception in 2007, Curetis AG has developed the versatile Unyvero™ instrument platform which handles disease-specific disposable cartridges for the analysis of various marker panels, covering both pathogens and antibiotic resistance genes. The Unyvero™ platform combines a unique, fully automated sample preparation working with a comprehensive range of native clinical sample types, with isolation, amplification and highly multiplexed detection of DNA. The simplified, automated and uniform work flow enables testing at the point of need, eliminates operator-induced variations and ensures high-quality results in a short time frame. The first application, a solution for comprehensive pneumonia testing, has successfully completed extensive pre-clinical testing, is about to enter into pivotal clinical trials towards regulatory clearance and is scheduled to enter the European market as a CE-marked device in 2012.

Company News: Curetis AG Opens Unyvero™ Cartridge Production Facility

Curetis AG, an innovative molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic products for infectious diseases, today announced the opening of its state-of-the-art production facility for disposable Unyvero™ cartridges in Bodelshausen (near Tuebingen, Germany).

The fully automated manufacturing line in a clean room environment is designed to be fully cGMP compliant and offers scalability and flexibility to meet the growing demands of clinical trials and commercialization with the scheduled 2012 EU launch of the Unyvero P50™ pneumonia cartridge.

Initial production capacity is 100,000 p.a. which may be easily expanded to an annual production capacity of 1 mio. cartridges. First product is the Unyvero™ P50 pneumonia cartridge for the identification of 17 pneumonia pathogens and 22 of their clinically most relevant antibiotic resistance markers.

Read more on the Curetis website.

Company News: Curetis AG Successfully Increases Series A Round to EUR 24.5 Million

Curetis AG, an innovative molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic products for infectious diseases, today announced an extension of its Series A financing, bringing the total size of the round to € 24.5 million. CD-Venture joined the funding as a new investor, while all of Curetis’ existing VC investors participated in the round. Several private investors also continued to co-invest.

Following the appointment of Oliver Schacht, PhD, as the new CEO of Curetis last month, this financing transaction is the first step towards funding next year’s commercial launch and roll-out of the Unyvero product platform together with the first CE marked IVD test cartridge for pneumonia and antibiotic resistances in Europe. The additional funds will allow Curetis to pursue a more aggressive strategy towards initiating a US clinical trial in H2-2011 with a goal of filing for FDA approval in 2012. This Series A financing positions Curetis as a solidly funded molecular diagnostics company with near-term commercial-stage products and its unique platform solution addressing a clear unmet medical need in the rapid diagnosis of infectious diseases and antibiotic resistance.

Curetis’ CEO Oliver Schacht will present an update on the company at the upcoming BioEquity 2011 in Paris. The presentation is scheduled for May 23, 2011, at 5:00 pm CET, Room Pont de Sully.

Further details can be found here.

 

1 … 4 5